1Gofuku J, Shiozaki H, Doki Y, et al. Characterization of soluble Ecadherin as a disease marker in gastric cancer patients. Br J Cancer,1998,78 : 1095-1101.
2Chart AO, Chu KM, Lam SK, et al. Soluble E-cadherin is an independent pretherapeutic factor for long-term survival in gastric cancer. J Clin Oncol,2003, 21:2288-2293.
3Mayer B, Johnson JP, Leitl F, et al. E-cadherin expression inprimary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res,1993,53 : 1690-1695.
4Gabbert HE, Mueller W, Schneiders A, et al. Prognostic value of Ecadherin expression in 413 gastric carcinomas, Int J Cancer, 1996,69 : 184-189.
4shaw RJ, liloglou T, Rosgers SN et al. promoter methylation of P16, RARbeta, E- cadherin, CYCLin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequeneing[ J ]. Br J Cancer, 2006, 94 (4) : 561.
5monga Sp. Hepalic adenosines: Presumed innocent untill proven to be beta -catenin mutated[J]. Hepatology, 2006,43 (3): 401.
6Filipek A. S100A6 and CacyBP/SIP- two protein discovered in ehrlich ascites tumor cells that are potentially involved in the degradation of beta - catenin[ J ]. Chemotherapy, 2006,52( 1 ) : 32.
